Literature DB >> 22131333

Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.

Jang Bae Moon1, Jung Ha Kim, Kabsun Kim, Bang Ung Youn, Aeran Ko, Soo Young Lee, Nacksung Kim.   

Abstract

SHIP is an SH2-containing inositol-5-phosphatase expressed in hematopoietic cells. It hydrolyzes the PI3K product PI(3,4,5)P(3) and blunts the PI3K-initiated signaling pathway. Although the PI3K/Akt pathway has been shown to be important for osteoclastogenesis, the molecular events involved in osteoclast differentiation have not been revealed. We demonstrate that Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. Inhibition of the PI3K by LY294002 reduces formation of osteoclasts and attenuates the expression of NFATc1, but not that of c-Fos. Conversely, overexpression of Akt in bone marrow-derived macrophages (BMMs) strongly induced NFATc1 expression without affecting c-Fos expression, suggesting that PI3K/Akt-mediated NFATc1 induction is independent of c-Fos during RANKL-induced osteoclastogenesis. In addition, we found that overexpression of Akt enhances formation of an inactive form of GSK3β (phospho-GSK3β) and nuclear localization of NFATc1, and that overexpression of a constitutively active form of GSK3β attenuates osteoclast formation through downregulation of NFATc1. Furthermore, BMMs from SHIP knockout mice show the increased expression levels of phospho-Akt and phospho-GSK3β, as well as the enhanced osteoclastogenesis, compared with wild type. However, overexpression of a constitutively active form of GSK3β attenuates RANKL-induced osteoclast differentiation from SHIP-deficient BMMs. Our data suggest that the PI3K/Akt/GSK3β/NFATc1 signaling axis plays an important role in RANKL-induced osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22131333     DOI: 10.4049/jimmunol.1101254

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

Review 1.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

2.  IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).

Authors:  Zhihong Chen; Lingkai Su; Qingan Xu; Jenny Katz; Suzanne M Michalek; Mingwen Fan; Xu Feng; Ping Zhang
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

3.  The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro.

Authors:  You Hwa Son; Seong Hee Moon; Jiyeon Kim
Journal:  Mol Cells       Date:  2013-10-22       Impact factor: 5.034

4.  Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Authors:  Linlin Xu; Khalid S Mohammad; Hao Wu; Colin Crean; Bradley Poteat; Yinghua Cheng; Angelo A Cardoso; Christophe Machal; Helmut Hanenberg; Rafat Abonour; Melissa A Kacena; John Chirgwin; Attaya Suvannasankha; Edward F Srour
Journal:  Cancer Res       Date:  2016-09-07       Impact factor: 12.701

5.  Fucoidan Prevents RANKL-Stimulated Osteoclastogenesis and LPS-Induced Inflammatory Bone Loss via Regulation of Akt/GSK3β/PTEN/NFATc1 Signaling Pathway and Calcineurin Activity.

Authors:  Sheng-Hua Lu; Yi-Jan Hsia; Kuang-Chung Shih; Tz-Chong Chou
Journal:  Mar Drugs       Date:  2019-06-10       Impact factor: 5.118

6.  The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.

Authors:  Kakeru Ozaki; Takanori Yamada; Tetsuhiro Horie; Atsushi Ishizaki; Manami Hiraiwa; Takashi Iezaki; Gyujin Park; Kazuya Fukasawa; Hikari Kamada; Kazuya Tokumura; Mei Motono; Katsuyuki Kaneda; Kazuma Ogawa; Hiroki Ochi; Shingo Sato; Yasuhiro Kobayashi; Yun-Bo Shi; Peter M Taylor; Eiichi Hinoi
Journal:  Sci Signal       Date:  2019-07-09       Impact factor: 8.192

7.  RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF-κB2 processing by IKKα.

Authors:  Rei Taniguchi; Hidefumi Fukushima; Kenji Osawa; Toshimasa Maruyama; Hisataka Yasuda; Falk Weih; Takahiro Doi; Kenshi Maki; Eijiro Jimi
Journal:  J Biol Chem       Date:  2014-01-31       Impact factor: 5.157

8.  Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.

Authors:  Jessica Lauriol; Janel R Cabrera; Ashbeel Roy; Kimberly Keith; Sara M Hough; Federico Damilano; Bonnie Wang; Gabriel C Segarra; Meaghan E Flessa; Lauren E Miller; Saumya Das; Roderick Bronson; Kyu-Ho Lee; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2016-06-27       Impact factor: 14.808

9.  Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells.

Authors:  Dong-Zhu Li; Qing-Xiang Zhang; Xiao-Xian Dong; Huai-Dong Li; Xin Ma
Journal:  J Bone Miner Metab       Date:  2013-11-07       Impact factor: 2.626

10.  LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.

Authors:  Jian Luo; Zhengfeng Yang; Yu Ma; Zhiying Yue; Hongyu Lin; Guojun Qu; Jinping Huang; Wentao Dai; Chenghai Li; Chunbing Zheng; Leqin Xu; Huaqing Chen; Jiqiu Wang; Dali Li; Stefan Siwko; Josef M Penninger; Guang Ning; Jianru Xiao; Mingyao Liu
Journal:  Nat Med       Date:  2016-04-11       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.